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Abstract 
Human Immunodeficiency Virus (HIV) suppresses the immune system by attacking T 
cells, leading to the development of acquired immunodeficiency syndrome (AIDS). HIV affects 
over 30 million people around the world and 1.6 million people in Kenya. On August 18, 1987, 
the FDA sanctioned the first human testing of a candidate vaccine for HIV. Currently, multiple 
HIV vaccines—projected to be on the market in five to ten years—are being tested for efficacy 
and safety. The goal of this study was to explore opinions related to the HIV vaccine so that 
there is a guide for future policy development in Western Kenya. This study included a survey 
and focus groups taken from a convenience sample at various locations within Kisumu in 
Kisumu County and Sidindi in Siaya County. The study found that most participants would get 
vaccinated if the HIV vaccine became available (87.7%), and the majority of participants support 
a compulsory vaccination campaign for children (81.18%). 
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Community Perception the HIV Vaccine in Western Kenya:  
Acceptability, Potential Behavior Changes, and Views on Compulsory Vaccination 
Background and Introduction 
Human Immunodeficiency Virus (HIV) is a virus that suppresses the immune system by 
attacking the body’s CD4 cells, also known as T cells, and if left untreated, HIV can lead to 
acquired immunodeficiency syndrome (AIDS), which signals that the body’s immune system is 
severely suppressed (CDC, 2017). HIV is not curable, and once a person is infected, the 
individual has the HIV infection for life; HIV has three stages of infection (CDC, 2017). The 
first stage of infection is acute HIV infection, which occurs within two to four weeks after 
infection with individuals experiencing a flu-like illness, and the next stage of HIV infection is 
clinical latency in which a HIV positive person is asymptomatic (CDC, 2017). The last stage of 
infection is AIDS; AIDS signals that the individual is in the last stage of HIV infection, and the 
person is extremely vulnerable to opportunistic infections and cancers (CDC, 2017). Individuals 
can transmit HIV to others when infected by sharing bodily fluids through activities such as 
sexual contact, injection drug use, mother to child transmission, and blood transfusions (CDC, 
2017).  
HIV originated in chimpanzees in Central Africa as simian immunodeficiency virus 
(SIV), which scientists believe was transmitted to humans through infected blood from a hunted 
chimpanzee (CDC, 2017). The virus is believed to have then mutated, and it spread across Africa 
possibly as far back as the late 1800s (CDC, 2017). HIV was first detected in the United States in 
1981, when young, previously healthy, gay men started to get rare and aggressive forms of 
diseases, such as Kaposi’s Sarcoma and Pneumocystis carinii pneumonia, at higher rates than 
normal (HIV.gov, 2016). On June 5, 1981, the CDC’s Morbidity and Mortality Weekly Report 
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stated the oddity of the aggressive diseases in previously healthy, young men (HIV.gov, 2016). 
The CDC used the term AIDS for the first time in 1982, and the virus became widely known and 
highly stigmatized shortly after that (HIV.gov, 2016). By 1985, at least one case of HIV was 
reported in each region of the world, making it a pandemic, and the Food and Drug 
Administration (FDA) approved the first test for HIV (HIV.gov, 2016). In 1986, the International 
Committee on the Taxonomy of Viruses stated that the virus would be called HIV (HIV.gov, 
2016). In 1987, the FDA approved Zidovudine, the first antiretroviral drug for treatment of HIV 
and other nucleoside reverse transcriptase inhibitors (NRTIs) followed, but these medications 
were only able to suppress the virus for a short period of time (HIV.gov, 2016). In 1996, the New 
England Journal of Medicine advocated for the efficacy of combining two NRTIs in conjunction 
with protease inhibitors—a new kind of antiretroviral therapy—naming this combination therapy 
highly active antiretroviral therapy (HAART) (HIV.gov, 2016). Also in 1996, the FDA approved 
the first viral load test and the first non-nucleoside reverse transcriptase inhibitor (NNRTI)—
nevirapine (HIV.gov, 2016). In 1997, the FDA approved Combivir, which made it easier for 
people to take their HIV medication by combining two medications into one tablet, and it was 
reported in the same year that more people were becoming resistant to protease inhibitors 
(HIV.gov, 2017). UNAIDS, global health groups, and five pharmaceutical companies announced 
a collaboration to reduce the price of HIV/AIDS medications in developing countries, and in 
2002, the evidence of a rise in drug resistance came to light (HIV.gov, 2016). In December 2006, 
a University of Illinois Chicago study found that medical male circumcision reduced the risk of 
contracting HIV during sexual intercourse, paving the way for widespread advocacy for 
voluntary medical male circumcision throughout Kenya and other parts of Africa (HIV.gov, 
2016). In 2009, the FDA approved the 100th antiretroviral drug for the treatment of HIV 
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(HIV.gov, 2016). In 2010, a study in South Africa showed a 39% decrease in likelihood of 
contracting HIV when anti-retroviral-based vaginal microbicides were used, and the NIH 
announced that pre-exposure prophylaxis (PrEP)—a daily oral dose of antiretroviral therapy—
can reduce the risk of contracting HIV in HIV-negative people (HIV.gov). In 2011, a CDC study 
found that PrEP could reduce HIV transmission to HIV-negative partners in heterosexual 
relationships (HIV.gov, 2016). In 2012, the FDA approved Truvada for PrEP to reduce the risk 
of contracting HIV in HIV-negative adults (HIV.gov, 2016). There are multiple drug classes now 
currently on the market including nucleoside reverse transcriptase inhibitors, non-nucleoside 
reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors, integrase 
inhibitors, pharmacokinetic enhancers, and combination HIV medicines (United States 
Department of Health and Human Services [USDHHS], 2017). HIV can be managed if the 
person seeks treatment with antiretroviral therapy, and if taken properly, this lessens their 
chances of transmitting the disease to another person, as well as decreases the probability of 
progressing to AIDS (CDC, 2017). 
On August 18, 1987, the FDA sanctioned the first human testing of a candidate vaccine 
for HIV (HIV.gov, 2016). In 1996, the International AIDS Vaccine Initiative (IAVI) was formed 
to quicken the search for an effective HIV vaccine (HIV.gov, 2016). In 1997, President Bill 
Clinton called for the creation of an AIDS vaccine research center at the National Institutes of 
Health (NIH) with the center officially opening in 1999 (HIV.gov, 2016). Also in 1999, VaxGen 
began conducting human vaccine trials in Thailand for an HIV vaccine, but in 2003, the 
company announced the vaccine trial failed to reduce overall infection rates among those 
vaccinated (HIV.gov, 2016). In 2000, President Bill Clinton announced the launch of the 
Millennium Vaccine Initiative to promote the development and distribution of vaccines for HIV, 
COMMUNITY PERCEPTION OF THE HIV VACCINE IN WESTERN KENYA  8 
Tuberculosis, and Malaria (HIV.gov, 2016). On May 18, 2001, there was the first HIV Vaccine 
Awareness Day (HIV.gov, 2016).  In 2004, a consortium of government and private sector 
companies was created to design and coordinate research to find an effective HIV vaccine 
(HIV.gov, 2016). In 2009, a vaccine trial run by the U.S. Military HIV Research Program and 
the Thai Ministry of Health found, with modest results, that a vaccine could prevent HIV 
infection (National Institutes of Health [NIH], 2016). In November 2016, the NIH and partners 
launched a phase 2b/3 HIV vaccine trial in 15 sites throughout South Africa, enrolling HIV-
negative sexually active men and women between the ages of 18 to 35 years (National Institutes 
of Health [NIH], 2016). In addition, Johnson and Johnson—an American-based global 
pharmaceutical company—announced in September 2017 that the company will launch large-
scale efficacy testing for their HIV vaccine in women between the ages of 18-35 in five African 
countries (McCarthy, 2017). Multiple HIV vaccines are now being tested in various countries 
with the hope that one of these vaccines will be effective and safe, and it is projected that a HIV 
vaccine could be on the market within the next 5 years (NIH, 2017) (McCarthy, 2017). 
 In this study, the researcher investigated community perception of the HIV vaccine by 
collecting surveys and conducting focus groups in the hope of collecting valuable insight into the 
opinions of people in Western Kenya in relation to the HIV vaccine, which will hopefully inform 
policy and further research. The goals of this study were to explore the acceptability of a HIV 
vaccine, assess possible behavior changes, and evaluate support for compulsory vaccination 
programs. 
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Statement of the Problem 
There are an estimated 36.7 million people living with HIV around the world—1.8 
million of those children (HIV.gov, 2016). The number of women living with HIV continues to 
increase globally with adolescents and young women being particularly vulnerable to infection 
(Avert, 2017). Acceptance of a HIV vaccine is necessary as drug resistance to many 
antiretroviral drugs continues to rise (HIV.gov, 2016). Prevention is the most cost-effective way 
to tackle HIV, and a HIV vaccine would be one of the most effective prevention strategies 
(Avert, 2017). There is currently very little data on the acceptability of the HIV vaccine in 
Kenya, as well as no documentation of possible behavior changes that could result if people were 
to get immunized. In addition, it would be beneficial to know how Kenyans feel about a 
compulsory vaccine, particularly a compulsory HIV vaccine, because it could inform policy. 
 
Objectives 
To investigate opinions of individuals in Western Kenya surrounding the HIV vaccine, 
specifically: 
o To explore the acceptability of a HIV vaccine, such as the likelihood of parents having 
their children immunized and the efficacy threshold they would consider acceptable. 
o To assess possible behavior changes should a HIV vaccine be released onto the market. 
o To evaluate the support of a compulsory HIV vaccine. 
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The Setting 
Kenya 
HIV was found in Kenya in 1984, and over 10% of the population was infected by the 
mid-1990s, which put huge demands on the healthcare system and caused mortality in the 
country to rise (Avert, 2017). There are about 1.6 million people living with HIV in Kenya, and 
the country has an adult HIV prevalence of 5.4% with a prevalence as high as 20% in some 
counties (Avert, 2017). Of HIV-infected adults, 64% are on antiretroviral treatment, while 65% 
of HIV-infected children are on antiretroviral treatment (Avert, 2017). There is still considerable 
stigma around HIV in Kenya, which can prevent people from accessing services and treatment 
(Avert, 2017). In 2015, it was estimated that up to 660,000 children were orphaned by AIDS 
(Avert, 2017). It is also noted that HIV disproportionately affects the Western part of the country 
(Avert, 2017). Vulnerable populations to HIV in Kenya include men who have sex with men, 
people who inject drugs, sex workers, and women (Avert, 2017). In Kenya, more women are 
living with HIV than men with young women accounting for 21% of all new infections with a 
prevalence significantly higher than males of the same age (Avert, 2017). It is argued the HIV 
vaccine will have the largest effect on young women because it can prevent them from ever 
getting infected, and it could have a very positive impact in high-incidence areas, such as 
Kisumu County and Siaya County—the location of this research study. The majority of the 
people in both Kisumu and Siaya are members of the Luo tribe. Both Kisumu and Siaya counties 
were part of the Nyanza province before devolution was implemented in the Constitution of 
Kenya 2010 (Kenya’s devolution). 
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Kisumu 
Kisumu—located on the shores of Lake Victoria—is the third largest city in Kenya. 
Because of the location on the shores of Lake Victoria, Kisumu is an area prone to tropical 
diseases, and it is also one of the areas in the country hardest hit by the HIV epidemic with 
19.3% of the total population affected—the third highest prevalence in the country (Open Data 
Blog, 2014). The study was conducted in the area of Kondele within Kisumu, which is a slum 
outside the main central business district of Kisumu (personal communication with CHV, Ayub 
Saidi). This area has one of the highest numbers of commercial sex workers in the area where 
women sell their services to lorry truck drivers and local residents (personal communication with 
CHV, Ayub Saidi). This makes the area a hotbed for HIV to spread easily between sex workers, 
clients, and the clients’ wives. Luckily, In Kisumu County, 104% of people who need 
antiretroviral drugs have access to them, which means that Kisumu has a supply in excess of 
what is required to treat their HIV positive population (HIV Situation in Kenya).  
Siaya 
Sidindi is a village located within Siaya county along the Kisumu Busia road—a major 
transportation route in Western Kenya. The people in this village primarily work in the market or 
farm their land, as well as keep livestock (personal communication with CHV, Monica). Siaya 
County has the second highest HIV prevalence in the country—23.7%, and 82% of those 
requiring antiretroviral treatment have access to these medications (HIV Situation in Kenya).  
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The map above shows the location of Sidindi with the red marker and Kisumu with the blue dot. 
 
Literature Review 
Sung-Jae Lee, Peter A. Newman, Naihua Duan, and William Cunningham explore 
attitudes related to vaccination and aim to develop a scale in which to examine HIV vaccine 
acceptability (2014). The researchers report the results with little bias, and the researchers make 
a compelling argument for the collection of attitudes now for the successful roll-out of HIV 
vaccinations in the future (Lee, S.-J., Newman, P. A., Duan, N., & Cunningham, W. E., 2014). 
The authors are all researchers at reputable universities, and this platform has been used for 
multiple studies to collect data (Lee et al., 2014). The results are supported by evidence, given 
the attitude scale was created from data collected as part of the large survey. The researchers 
identified four factors that affected vaccine acceptability, which were mistrust, HIV vaccine 
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social concerns, risk compensation, and altruistic vaccination (Lee et al., 2014). This work is 
investigating attitudes surrounding a HIV vaccine now before it is released, which provides 
insight into what apprehension and fear people have surrounding the vaccine. 
In a study of pregnant mothers in Kenya, Carey Farquhar, Grace C. John-Stewart, Francis 
N. John, Marjory N. Kabura, and James N. Kiarie investigate the willingness of these mothers to 
participate in research studies, as well as their views on vaccine acceptability (2006). They found 
that almost all of the mothers would vaccinate their infant against HIV, but the number of 
mothers that said they would vaccinate against HIV if it required trips to the clinic every 3 
months declined (Farquhar, C., John-Stewart G.C., John F.N., Kabura M.N., & Kiarie J.M., 
2006). The authors are all experts in their fields, and there is limited bias in this study. The 
researchers’ sample size was over 800 women, which provides strong evidence for their findings 
(Farquhar et al., 2006). This work shows that mothers want to have their children vaccinated, but 
a potential barrier to vaccination is the amount of doses a child would need (Farquhar et al., 
2006). This is beneficial for public health professionals to know before they roll out potential 
vaccination campaigns for HIV in the future. 
The Kenya Demographic and Health Surveillance Survey provides very useful data on 
HIV/AIDS in Kenya, as well as knowledge, attitudes, and behavior surrounding the virus 
(Ikamari, L., Wanyungu, J., Muttunga, J. Khasiani M., Awes, A.A., 2014). This data is collected 
at homes by trained interviewers, which makes this data very reliable (Ikamari et al., 2014). This 
is a program supported by KEMRI, which provides the survey with a strong ethical backing and 
credibility. This source provides baseline data on current rates of HIV/AIDS-related knowledge, 
behavior, and attitudes, which will provide useful data in the future if an HIV vaccine is released 
because researchers can see if risk behaviors change. Also, this data shows that knowledge and 
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awareness of HIV/AIDS is widespread in Kenya with most people having some knowledge of 
HIV, which is useful to know before interviewing people. 
In Los Angeles, California, Peter A. Newman, Sung-Jae Lee, Ellen T. Rudy, Allison 
Diamant, Naihua Duan, Terry Nakazano, and William Cunningham investigate the 
characteristics and attitudes associated with support for compulsory HIV vaccination (2014). The 
authors have a large sample size, which gives ample evidence for support of their data (Newman 
et al., 2014). The researchers found that just under half of the people surveyed agreed with 
compulsory vaccination for HIV (Newman et al., 2014). The authors are all researchers at 
reputable universities in the United States, and the LA VOICES platform is used to collect data 
on multiple issues (Newman et al., 2014). This study contributes to the literature on opinions 
surrounding HIV vaccination because they have data from a large city in the United States on the 
acceptability and endorsement of a compulsory HIV vaccine. 
Allison L. Friedman, Kelvin O. Oruko, Melissa A. Habel, Jessie Ford, Jennine Kinsey, 
Frank Odhiambo, Penelope A. Phillips-Howard, Susan A. Wang, Tabu Collins, Kayla F. 
Laserson, and Eileen F. Dunne investigate opinions surrounding HPV vaccination in Kenya prior 
to the initiation of vaccination programs for preteen girls; the study includes research into 
cervical cancer related knowledge, attitudes, beliefs, and acceptability (2014). The researchers 
conducted focus groups with caregivers, as well as key-informant interviews and found that the 
acceptability of the vaccination was high if there was support from trustworthy agencies and 
sensitization of communities, but there were concerns related to vaccine safety (Friedman et al., 
2014). The authors are all researchers at reputable universities and organizations, and the study 
sites were located within the KEMRI demographic health surveillance system area (Friedman et 
al., 2014). This study provides valuable insight into issues surrounding preteen vaccines in 
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Western Kenya. Since this study was done before the program was implemented, it is a clear 
indication of need to collect vaccine acceptability data before a vaccine is available to the 
general public. 
In a study on HPV vaccination in Kenya, Sylvia Becker-Dreps, Walter Agingu Otieno, 
Noel T. Brewer, Kawango Agot, and Jennifer S. Smith investigate the knowledge and interest 
surrounding HPV vaccination among women, and the researchers found that most mothers were 
willing to have their daughters vaccinated against HPV if it prevented cervical cancer (2010). 
The study also found that the women preferred if the vaccine was inexpensive and required few 
doses (Becker-Dreps, S., Otieno W.A., Brewer, N.T., Agot, K., Smith, J.S., 2010). The 
researchers are from a reputable university in the United States, as well as a reputable research 
organization in Kisumu, and the sample size of 147 individuals provides strong support for the 
data they found (Becker-Dreps et al., 2010). This study is a good model for a vaccine 
acceptability study in Kenya, and a good platform for evaluating HIV vaccine acceptability. 
Since this study was done before any HPV vaccination programs were implemented, it can help 
to inform policy surrounding the vaccine, which is beneficial. 
While there have been studies conducted in Los Angeles about HIV vaccine acceptability 
and views surrounding compulsory vaccination, few studies have been done in Kenya or Sub-
Saharan Africa surrounding HIV vaccination. Since Sub-Saharan Africa is the area in the world 
most affected by HIV, more studies should be done in this area to investigate opinions 
surrounding HIV vaccine acceptability and compulsory vaccination. Cultures differ in various 
parts of the world, so the culture surrounding vaccines in Africa could be quite different from 
that in the United States. Adolescent girls and young women are the most affected by HIV in 
Sub-Saharan Africa, so the HIV vaccine could have the largest effect on this age group if the 
COMMUNITY PERCEPTION OF THE HIV VACCINE IN WESTERN KENYA  16 
vaccine were to come to market. However, to ensure that girls are vaccinated before their first 
sexual encounter, parents will need to consent to their children being immunized. Therefore, the 
target population for this study was parents of young children, preteens, and adolescents because 
these age groups will need the vaccine before first sexual interaction. It will be crucial to have 
information regarding opinions on the HIV vaccination before it is released on the market 
because it will give health facilities and public health professionals time to prepare and 
implement informed vaccination campaigns that will work for the area. 
 
Methodology 
In this study, opinions relating to the HIV vaccine were explored including the 
acceptability of the HIV vaccine, possible behavior changes related to the vaccine, and the 
support of a compulsory vaccination program for the HIV vaccine. The data was collected in 
surveys that consisted of demographic information, vaccination history, opinions on vaccination, 
opinions on people with HIV, and opinions on the HIV vaccination, as well as in focus groups in 
which six questions were asked that expanded upon what was asked in the survey. The surveys 
took approximately 10 minutes to complete per participants, and the focus group took about 30 
minutes to complete. The surveys were available in both English and Swahili, and the focus 
group questions were written in both English and Swahili with the Community Health Volunteer 
(CHV)V for each area translating and clarifying with the local Luo language when necessary. 
The target population of this study was parents who were over the age of 18, and the age of the 
respondent as well as their parental status was confirmed by the community health volunteers in 
each of the areas. 
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In Kondele, the surveys were collected by traveling home-to-home, utilizing a 
convenience sample, as well as by stopping people on the street that were willing to take the 
survey. The participants were sought out and divided into one of two groups by income level—
low-income and middle-income. The income level of the participant was determined by the 
structure of the home they resided within. Low-income homes were classified by mud-thatched 
homes, and middle-income was determined by structures made of cement block or brick. The 
participants for the focus groups were recruited through local community health volunteers in 
Kondele. In Sidindi, the surveys were collected by traveling home-to-home utilizing a 
convenience sample, as well as by distributing surveys to people in the market area of town. 
Income level was not noted for the participants in Sidindi. The participants for the focus group 
were recruited from the previous participants in the survey, and the participants were asked to 
attend the focus group the next day. 
In Kondele, 101 surveys were completed, as well as two focus groups—one for low-
income with 13 participants and one for middle-income with 10 participants. In Sidindi, 90 
surveys were completed, as well as one focus group with 9 participants. It was decided to collect 
about 100 surveys in each area because of convenience and time limitations. 
 
Limitations 
The limitations of this research study consisted of language barriers between the 
researcher and participants, as well as the researcher and the community health volunteers. 
Because fluent Swahili and fluent Luo are not spoken by the researcher, some information was 
lost in translation in the focus group discussions. In addition, due to the election ruling by the 
Supreme Court in Kenya at the time of research, it was not safe to conduct research as usual, and 
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the community health volunteer had to conduct the middle-income focus group alone, which led 
to the researcher getting information on the focus group from a second-hand source. 
Furthermore, another limitation is that the community of Sidindi may not accurately represent 
every other rural community in Western Kenya, but since this community was mostly Luo—the 
predominant ethnic group in Western Kenya, it can be used to predict the views of others in 
Western Kenya to some extent. 
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Results 
Demographics of Study Participants (n=193) 
Variable Options Number (%) 
 
Highest Attained Level of 
Education 
No schooling 1 (0.52%) 
Primary School 63 (32.98%) 
Secondary School 78 (40.84%) 
College 36 (18.85%) 
Degree 13 (6.81%) 
 
 
Religion 
Anglican 72 (37.5%) 
Catholicism 53 (27.6%) 
Islam 13 (6.77%) 
Seventh-Day Adventist 17 (8.85%) 
Pentecostal 18 (9.42%) 
Other 19 (9.9%) 
 
 
 
Age 
Below 25 33 (17.1%) 
26-30 39 (20.21%) 
31-35 39 (20.21%) 
36-40 25 (12.95%) 
41-45 16 (8.29%) 
46-50 21 (10.88%) 
Over 50 20 (10.36%) 
 
Residence 
Kisumu County 98 (51.31%) 
Siaya County 93 (48.69%) 
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Do they own property? 
Yes 89 (49.72%) 
No 90 (50.28%) 
 
Gender 
Male 65 (33.85%) 
Female 127 (66.15%) 
Have they received 
immunizations in the past? 
Yes 171 (89.53%) 
No 20 (10.47%) 
 
Do you feel that vaccines are generally good or bad? 
Answer Frequency of Answer (%) 
Good 181 (92.26%) 
Bad 2 (1.05%) 
Not sure 7 (3.68%) 
Total 190 
 
 
Do you feel that vaccines are generally good or bad?
Good Bad Not sure
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Do you feel that vaccines have harmful effects? 
Answer Frequency of Answer (%) 
Yes 32 (17.11%) 
No 120 (64.17%) 
Not sure 35 (18.72%) 
Total 187 
 
 
 
 
 
 
 
Do you feel vaccines have harmful effects?
Yes No Not sure
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Do you support compulsory vaccination programs? 
Answer Frequency of Answer (%) 
Yes 152 (81.28%) 
No 32 (17.11%) 
Not sure 3 (1.6%) 
Total 187 
 
 
 
 
 
 
 
Do you support compulsory vaccination programs?
Yes No Not sure
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If a HIV vaccine were available, would you get immunized? 
Answer Frequency of Answer (%) 
Yes 164 (87.7%) 
No 13 (6.95%) 
Not sure 10 (5.35%) 
Total 187 
 
 
 
 
 
 
 
If an HIV vaccine were available, would you get 
immunized?
Yes No Not sure
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If a HIV vaccine were available, would you get your child immunized? 
Answer Frequency of Answer (%) 
Yes 165 (87.3) 
No 15 (7.94%) 
Not sure 9 (4.76%) 
Total 189 
 
 
 
 
 
 
If an HIV vaccine were available, would you get your 
child immunized?
Yes No Not sure
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If a HIV vaccine were available, would you get immunized if it required one dose? 
Answer Frequency of Answer (%) 
Yes 149 (80.1%) 
No 20 (10.75%) 
Not sure 17 (9.14%) 
Total 186 
 
If a HIV vaccine were available, would you get immunized if it required two doses to be 
fully effective? 
Answer Frequency of Answer (%) 
Yes 114 (61.29%) 
No 42 (22.58%) 
Not sure 30 (16.13%) 
Total 186 
 
If an HIV vaccine were available, would you get immunized if it required three or more 
doses to be fully effective? 
Answer Frequency of Answer (%) 
Yes 108 (59.01%) 
No 44 (24.04%) 
Not sure 31 (16.94%) 
Total 183 
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If an HIV vaccine were available, would you get
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Would you be concerned about how your sexual partner would react to you getting a HIV 
vaccine? 
Answer Frequency of Answer (%) 
Yes 134 (72.43%) 
No 32 (17.3%) 
Not sure 19 (10.27%) 
Total 185 
 
Would you be concerned about how your family would react to you getting a HIV vaccine? 
Answer Frequency of Answer (%) 
Yes 135 (72.58%) 
No 35 (18.82%) 
Not sure 16 (8.6%) 
Total 186 
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Would you get an HIV vaccine if it was not 100% effective against the virus? 
Answer Frequency of Answer (%) 
Yes 87 (42.8%) 
No 70 (38.46%) 
Not sure 25 (13.7%) 
Total 182 
 
 
 
 
 
 
 
Would you get an HIV vaccine if it was not 100% effective 
against the virus?
Yes No Not sure
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Would you support a compulsory HIV vaccine for all children? 
Answer Frequency of Answer (%) 
Yes 151 (81.18%) 
No 23 (12.37%) 
Not sure 12 (6.45%) 
Total 186 
 
Would you support a compulsory HIV vaccine for all HIV negative adults? 
Answer Frequency of Answer (%) 
Yes 143 (76.47%) 
No 31 (16.58%) 
Not sure 13 (6.95%) 
Total 187 
 
Would you support a compulsory HIV vaccine for all HIV negative adults and children? 
Answer Frequency of Answer (%) 
Yes 152 (81.28%) 
No 25 (13.37%) 
Not sure 10 (5.35%) 
Total 187 
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If the HIV vaccine was available, would you stop using condoms during sex? 
Answer Frequency of Answer (%) 
Yes 38 (20.11%) 
No 144 (76.19%) 
Not sure 7 (3.7%) 
Total 189 
 
 
 
 
 
 
If a HIV vaccine were available, would you stop using 
condoms during sex if immunized? 
Yes No Not sure
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If a HIV vaccine was available and you were immunized, would you engage in riskier 
sexual behavior? 
Answer Frequency of Answer (%) 
Yes 22 (11.52%) 
No 159 (83.25%) 
Not sure 10 (5.24%) 
Total 191 
 
 
 
 
 
If a HIV vaccine were available and you were immunized, 
would you engage in riskier sexual behavior?
Yes No Not sure
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If a HIV vaccine was available and you were immunized, would you engage in behavior 
you did not engage in previously? 
Answer Frequency of Answer (%) 
Yes 24 (12.7%) 
No 154 (81.48%) 
Not sure 11 (5.82%) 
Total 189 
 
 
 
 
 
 
If a HIV vaccine were available and you were immunized, 
would you engage in behavior you did not engage in 
previously?
Yes No Not sure
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If men were to be immunized with a HIV vaccine, do you think that they would still get 
circumcised? 
Answer Frequency of Answer (%) 
Yes 158 (84.49%) 
No 19 (10.16%) 
Not sure 10 (5.35%) 
Total 187 
 
 
 
 
 
 
 
If men were to be immunized with the HIV vaccine, do 
you think that they would still get circumcised?
Yes No Not sure
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Discussion and Analysis 
Introduction 
The objective of the research study was to investigate the opinions of individuals in 
Western Kenya surrounding the HIV vaccine, specifically the acceptability of the vaccine, 
potential behavior changes that could result from an individual being vaccinated, and support for 
a compulsory HIV vaccination campaign.  
 
 
Acceptability of the HIV Vaccine 
One of the key questions asked during this study evaluated if participants would be willing 
to get vaccinated with the HIV vaccine when it became available to the general public. In the total 
responses, 87.7% of participants answered that they would get immunized themselves if the 
vaccine were to come to market. Comments from the focus groups noted that all ages are affected 
by HIV and that most homes are affected in some way. A key point that one participant noted was 
that it is more expensive to treat HIV than it is to prevent it, so a vaccine could help alleviate the 
burden on the health care system. HIV has had a drastic impact on the healthcare systems of the 
countries most ravaged by the epidemic, and a vaccination could create a large-scale preventative 
measure that is quick, easy, and efficient. Currently prevention is largely focused on behavioral 
changes and pre-exposure prophylaxis, but these prevention efforts leave a lot of room for error. 
If the vaccine would be given properly and people showed up to all the required doses, vaccination 
could be a prevention effort that finally slows the epidemic. While this study had a smaller sample 
size than comparable research studies, the results differ from the other literature on HIV vaccine 
acceptability. As a participant in the focus group stated, HIV is a major problem in Kenya and no 
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family is left untouched. Thus, this could lead to more support for vaccination, as well as account 
for the high number of individuals that indicated they would be willing to be vaccinated 
themselves. The support for vaccination in Western Kenya should be noted to inform policy when 
the vaccine is available to the general public so that individuals can have access to the vaccine as 
quickly as possible. It is estimated that about 7,500 young women are infected with HIV every 
week around the world, so the vaccine could have a major impact in incidence as soon as 
widespread vaccination efforts are implemented (AVERT). People in Western Kenya want help, 
and they desire something that will finally have a drastic impact on HIV. As a participant in the 
focus group in Sidindi said: “We don’t want to swallow drugs everyday. We’re tired of people 
dying. We need help.” A large-scale vaccination campaign implemented by trained community 
health volunteers that go home-to-home could be an efficient way to ensure all people that want 
the vaccine have access to it. This research study has shown that most people surveyed were 
willing to be vaccinated, and preparation for large-scale vaccination campaigns should start to take 
shape now so that the most people possible have access to the vaccine as soon as possible after it 
is released. 
Children arguably need the vaccine most because this reduces their chances of contracting 
HIV when they get older. However, since parents make health care decisions for their children, 
parents are the ones that need to decide to have their children vaccinated with the HIV vaccine. 
Women and girls ages 10-24 are most likely to contract HIV, and the HIV vaccine will only be 
effective if given before the person contracts HIV. Thus, children need to get the vaccine before 
first sexual contact to have the optimal amount of prevention opportunities. Participants at the 
focus groups in Kondele noted that the age of first sexual intercourse is usually around twelve for 
girls, as young as nine, and for boys around the age of ten. This means that children would have 
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about eight years of sexual encounters before they were able to make their own decisions about 
vaccination, so parents need to consent to have their children vaccinated at a young age before first 
sexual encounter. In the study, it was found that 87.3% of parents would be willing to have their 
children vaccinated with the HIV vaccine, and participants state that they would be willing to have 
their kids vaccinated because of early age of first sexual intercourse and the fact that HIV can be 
transmitted through blood contact. However, some parents still maintained that children did not 
need it because they did not have sex. There are issues of rape and defilement in the community, 
so parents would be willing to have their children protected from HIV to some extent at a young 
age.  Other parents had issues with the efficacy of the virus. One parent stated that they would 
vaccinate their child if the vaccine was 100% effective against the virus, while another parents 
stated they would vaccinate their child if the vaccine was more than 80% effective. These results 
go along with the results found by Farquhar, John-Stewart, John, Kabura, and Kiarie in a study of 
over 800 pregnant mothers in Kenya (Farquhar et al., 2006). The authors found that almost all of 
the mothers would vaccinate their children against HIV (Farquhar et al., 2006). It seems that 
parents who have seen the impact of HIV in their communities are willing to have their children 
vaccinated with a safe and effective vaccine. While parents would agree to have their children 
immunized, there might be issues in the future with parents not being willing to vaccinate their 
children against a disease that is sexually transmitted. In the future, parents will need to make the 
decision to vaccinate their children against HIV, and the health care system needs to enable them 
with all the tools to make that decision in an educated manner. 
The HIV vaccine is currently in human clinical trials, and the researchers are evaluating 
effectiveness of the vaccine and the appropriate dosage regimen (NIH, 2016). The HIV vaccine 
could require any number of doses to be effective, and in this study, the researcher attempted to 
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evaluate the willingness of people to get vaccinated depending on number of doses required to be 
fully effective. It was found that 80.1% of individuals would get vaccinated if it required one dose 
to be fully effective, but the amount of people that would get vaccinated if it required two doses 
was 61.29%. Individuals that would get vaccinated if it required three or more doses were 59.01% 
of study participants. The amount of people that would get the vaccine if it required two doses 
drops significantly from the amount of people who would get vaccinated if it required one dose. 
This could be due to a number of reasons, such as difficulty of getting to a clinic and the inability 
to track when they will need the vaccine. In a study of pregnant mothers in Kenya, Carey Farquhar, 
Grace C. John-Stewart, Francis N. John, Marjory N. Kabura, and James N. Kiarie investigated the 
willingness of mothers to have their infants vaccinated with the HIV vaccine, but the amount of 
mothers that would have their children vaccinated if it required trips to the health clinic every three 
months decreased significantly (2006). The results of this study indicate the same pattern that was 
found in the research study. Vaccinations that require more than one dose can become an 
inconvenience to parents who must take their children to the health clinic for all of their healthcare 
visits. Also, keeping track of the spacing and time of vaccinations can be difficult to manage. The 
healthcare system will need to create a creative plan to get people to come for multiple doses if 
that is what the vaccine requires. This could involve calling the individuals or parents to remind 
them of appointments to get vaccinated. The vaccination program could also be implemented by 
community health volunteers that vaccinate all people and children that are willing, and then return 
to those houses when the subsequent doses are required. This means that one person has to keep 
the schedule for the vaccines rather than each individual person. Also, a crucial component to a 
vaccine regiment that has multiple does is that the healthcare clinic must have the required doses 
for everyone that needs them at the time they come in for the vaccination. Shortages of vaccines 
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could jeopardize the vaccine programs as people become frustrated and do not return to the clinic 
for the next doses. Policy implementation and a well thought out vaccination campaign will be 
necessary for a successful roll-out of a vaccine that requires multiple doses. 
Perception of family members and sexual partners can have an impact on decision making. 
In this research study, two questions were asked that attempted to evaluate how the participants 
thought their family and their sexual partners would react to them getting an HIV vaccine. In the 
study, 72.43% of participants surveyed indicated that they were concerned about how their sexual 
partner would react to them getting a HIV vaccine, while 72.58% were concerned about how their 
family would react to them getting a HIV vaccine. In the L.A. VOICES survey, Sung-Jae Lee, 
Peter A. Newman, Naihua Duan, and William Cunningham were investigating HIV acceptability 
in Los Angeles, California, and they found that among social concerns related to getting the 
vaccine were concerns about how their families and sexual partners might react to them getting 
the HIV vaccine (2014). Almost all Kenyans have seen the impact of the HIV epidemic in some 
way, so with education programs in local communities, the potential stigma around the HIV 
vaccine could be mitigated. 
Since the HIV vaccine is currently in testing, there is no way at this time to know how 
effective the HIV vaccine will be against the virus, but the HIV vaccine study in Thailand showed 
modest protection against the virus (NIH, 2016). It was found in the study in Western Kenya that 
only 42.8% of study participants would get the vaccine if it was not 100% effective against the 
virus, which leads to questions about vaccine acceptability if it is only modestly effective. While 
even a modestly effective vaccine could lead to a reduction in HIV incidence, communities might 
have issues accepting a vaccine with low efficacy against HIV (NIH, 2016). Sung-Jae Lee, Peter 
A. Newman, Naihua Duan, and William Cunningham advocate that real-world vaccine efficacy 
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cannot be ignored as a potential contributor to HIV vaccine acceptability (2014). A vaccine is seen 
as a sense of security against a certain disease, but if a vaccine is not close to 100% effective, it 
can undermine people’s trust in the vaccine. However, in Kenya, if the vaccine is modestly 
effective, then people who are vaccinated need to be educated about the fact that the vaccine is 
modestly effective so that people do not engage in riskier sexual behavior and stop using condoms 
because of a false sense of security.   
 
Potential Behavior Changes 
The fear among many experts and local community members is that a HIV vaccine could 
actually lead to an increase in other sexually transmitted diseases because of the sense of security 
against HIV that the vaccine will provide (Painter et al., 2017). In the study, it was found that 
76.19% answered they would not stop using condoms during sex if immunized. However, 20.11% 
said they would stop using condoms during sex, which could still lead to an increase in other 
sexually transmitted diseases among this group. In addition, 83.25% said they would not engage 
in riskier sexual behavior as a result of being vaccinated, while 84.49% said they would not engage 
in behavior they did not engage in previously if vaccinated. Even though most people answered 
that they would not change their sexual behavior as a result of being vaccinated, there is still a 
large number of people that answered they would. Julia E. Painter, Ralph J. DiClemente, Lauren 
Jimenez, Theron Stuart, Jessica M. Sales, and Mark J. Mulligan attempted to investigate potential 
behavior changes in conjunction with a HIV vaccine trial in Atlanta, and they found that one of 
the motivators for participating in the study was to feel safer having unprotected sex (2017). 
However, this study was done in a community in Atlanta, and it might not be an accurate 
comparison for the area in which this study was conducted. Behavior might change as a result of 
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a HIV vaccine, but people need a way to stop the spread of HIV. It is a trade-off because protection 
from HIV may lead people to stop using condoms that they only used because of HIV. However, 
the benefit of the HIV vaccine and the potential burden it will alleviate on the population and the 
healthcare system in the future is too great to give up for the possibility that other sexually 
transmitted disease may increase. Education campaigns need to be emphasized that explain that 
the HIV vaccine is another preventative measure, but it is not to be used instead of safe sexual 
behavior. Potential behavior changes are impossible to truly know unless studies are implemented 
after the HIV vaccine is available to the general public, and studies should be done to evaluate 
these potential behavior changes at that time. 
 
Views on Compulsory Vaccination 
Compulsory vaccination refers to mandatory vaccinations that are usually required by the 
government of the country. This study attempted to evaluate support for compulsory vaccination 
programs, as well as support for compulsory vaccination programs for the HIV vaccine. It was 
found that 81.28% of people supported compulsory vaccination programs. For the HIV vaccine, 
81.8% of of study participants indicated support for a compulsory vaccination program for all 
children, and 76.47% of participants supported a compulsory vaccine for HIV negative adults. 
However, 81.28% of those surveyed supported a compulsory vaccine for all HIV negative adults 
and children. Participants in the focus groups noted that the vaccine should be compulsory to stop 
the spread of HIV, but others disagreed with the compulsory vaccination stating that researchers 
do not know how the vaccine will react with the human body and that HIV counseling services are 
not compulsory. Many stated that vaccine should be just for those who are HIV positive, which 
indicates a lack of awareness and knowledge about how vaccines work. One parent stated that the 
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vaccine should be compulsory for those who are HIV negative to: prevent transmission, save 
resources which can be used for individuals with HIV for treatment, and promote life. There was 
a difference in support for compulsory vaccination programs between rural and urban areas with 
71.6% of people in rural areas supporting compulsory vaccination programs, while 89% of those 
in urban areas supported compulsory vaccination programs. In Los Angeles, California, Peter A. 
Newman, Sung-Jae Lee, Ellen T. Rudy, Allison Diamant, Naihua Duan, Terry Nakazano, and 
William Cunningham investigated support for compulsory vaccination, and they found that just 
under half of those surveyed supported compulsory HIV vaccination programs (2014, pp. 5). This 
is in contrast to this study in which overall 81.28% of people supported compulsory vaccination, 
and 81.28% supported compulsory vaccination for all HIV negative adults and children. This area 
of Kenya has a high HIV rate, which may contribute to the desire for more people to want a 
widespread preventative measure, but further studies with larger sample sizes and a larger study 
area need to be done. While there was support for compulsory vaccination of all HIV negative 
adults and children, this leads to issues with testing because people may be unwilling to be tested 
for HIV and should not be forced to be tested if not desired. This could most likely be remediated 
by implementing a compulsory vaccination for all children and having an optional vaccine for 
adults. Larger studies should be implemented that could inform policy and potentially allow for a 
HIV vaccine campaign to be developed before the vaccine becomes available to the general public. 
 
Ramifications 
This study can be used as a basis for a large study in which vaccine acceptability and 
support for compulsory vaccination is further evaluated, as well as provide a basis for further study 
into potential behavior changes that may be the result of being vaccinated. In addition, policy needs 
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to be made now relating to the HIV vaccine because the longer it takes for policy once the vaccine 
is released, the more people there are where HIV infection could have been prevented. Thinking 
ahead is a crucial step for HIV vaccine policy, and the researcher hopes that this study can start 
the discussion. People in the communities that were studied seem to be really excited about the 
vaccine, and they were eager to ask questions about it. Discussion about the HIV vaccine and 
education programs should be started in these communities now.  
 
Conclusion 
Over 30 million people are infected with HIV in the world, and currently there are no 
vaccines on the market. Multiple HIV vaccines are currently in clinical trials, and there are hopes 
that the HIV vaccine could be available to the general public within five to ten years. In Kenya, 
there is little research on how communities feel about the vaccine, and in this study, community 
perception of the HIV vaccine was investigated, particularly acceptability, potential behavior 
changes, and support for compulsory vaccination programs. It was found that that majority of 
participants would be willing to be vaccinated with the HIV vaccine and vaccinate their children. 
In addition, participants largely answered that they would not change their current sexual 
behavior as a result of the vaccine, and the majority of participants supported compulsory 
vaccination programs for the HIV vaccine. There was some basic vaccine information lacking in 
the study participants, but most seemed very willing to accept the vaccine to finally have a viable 
solution for a reduction in HIV incidence.  
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Recommendations 
Further Study 
This study could be expanded by conducting the same study with a larger sample size 
taken from a wider geographic area that would give more reliable results. This study could also 
be extended by including more interviews to get more qualitative information that could help 
explain some of the quantitative results. In addition, it would be recommended to work with a 
community health volunteer or other community workers that know the area well and already 
have a trusting relationship with the community where the study is being conducted. In the 
future, the data could be analyzed further using statistical software to find patterns between 
demographic information and perception of the HIV vaccine. For instance, the effect gender, 
religion, income level, and location of the study participants has on their perception could be 
explored and investigated, but currently, this was not possible due to time constraints. 
 
Policy and Education 
It became evident throughout the study that basic vaccine information was lacking in the 
communities where the studies were implemented, and large-scale vaccine education programs 
could be beneficial to the community so that community members know how vaccines work, 
what vaccines they are receiving, the importance of vaccines, and the efficacy of vaccines. In 
addition, education programs related to the HIV vaccine will most likely be necessary to have a 
truly successful vaccination campaign. There were misconceptions that a HIV vaccine can cure 
HIV, and information like this needs to be corrected before the vaccine comes to market so that 
there is a smooth transition between vaccine release and large-scale vaccination of communities. 
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Community health volunteers can also be trained and utilized to implement the large-scale 
vaccine education campaigns, as well as to vaccinate individuals in the communities. Also, 
health facilities need systems for maintaining inventory of essential medications and vaccines in 
place now for the successful implementation of a HIV vaccination campaign in the future. Kenya 
needs to improve the issues with the healthcare system now rather than later, or many Kenyan 
citizens could miss out on the vaccine when it becomes available. This will require Kenya to 
improve healthcare policy related to vaccine awareness and administration.  
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Appendix A 
English Surveys and Interview Questions 
 
Section 1: This sections aims to get a summary of your demographic information and vaccination 
history. Please answer this section to the best of your ability. 
 
1. Are you over the age of 18? 
i. Yes 
ii. No 
2. What is your highest attained level of education? 
a. No schooling 
b. Primary school 
c. Secondary school 
d. College 
e. Degree 
3. What is your religion? 
a. Anglican 
b. Catholicism 
c. Islam 
d. Buddhism 
e. Baha’i 
f. Presbyterian 
g. Reformed 
h. Methodist 
i. Baptist 
j. Lutheran 
k. Pentecostal 
l. Eastern Orthodox 
m. New Apostolic Church 
n. Seventh-day Adventist Church 
o. Jehovah’s Witnesses 
p. United Pentecostal Church 
q. Branhamism 
r. The Church of Jesus Christ of Latter-days Saints 
s. Hinduism 
t. No religion 
u. Traditional Religion 
4. What is your age? 
a. 18-20 
b. 21-25 
c. 26-30 
d. 31-35 
e. 36-40 
f. 41-45 
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g. 46-50 
h. 51-55 
i. 56-60 
j. 61-65 
k. 66-70 
l. 71-75 
m. 76-80 
n. 81-85 
o. 86-90 
p. 91-95 
q. 96-100 
r. 100+ 
5. Where do you live? 
a. Kisumu County 
b. Siaya County 
6. Do you own property? 
a. Yes 
b. No 
7. What is your gender? 
a. Male  
b. Female 
8. Have you received immunizations in the past? 
a. Yes 
b. No 
9. If yes, were these immunizations given in childhood or adulthood? 
a. Childhood 
b. Adulthood 
c. Both childhood and adulthood 
d. Not applicable 
10. What diseases have you been vaccinated against? (Please answer this question to the best 
of your ability) 
a. Adenovirus 
b. Anthrax 
c. Diphtheria 
d. Hepatitis A 
e. Hepatitis B 
f. Haemophilus influenza type b (Hib) 
g. Human Papillomavirus 
h. Seasonal Influenza (Flu) 
i. Japanese Encephalitis 
j. Measles 
k. Meningococcal 
l. Mumps 
m. Pertussis 
n. Pneumococcal 
o. Polio 
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p. Rabies 
q. Rotavirus 
r. Rubella 
s. Shingles 
t. Smallpox 
u. Tetanus 
v. Tuberculosis 
w. Typhoid Fever 
x. Varicella 
y. Yellow Fever 
 
Section 2: This section aims to investigate your opinions regarding vaccines. Please answer 
truthfully. 
1. Do you feel vaccines are generally good or bad? 
a. Good 
b. Bad 
c. Not sure 
2. Do you feel that vaccines have harmful effects? 
a. Yes 
b. No 
c. Not sure 
3. Do you feel that vaccines should be available free of cost? 
a. Yes 
b. No 
c. Not sure 
4. Do you trust the health care system? 
a. Yes 
b. No 
c. Not sure 
5. Do you support compulsory vaccination programs? 
a. Yes 
b. No 
c. Not sure 
 
Section 3: This sections aims to investigate your opinions surrounding HIV/AIDS. Please answer 
truthfully.  
1. Do you have a negative or positive view of people with HIV? 
a. Positive 
b. Negative 
c. Neutral 
d. Not sure 
2. Can you contract HIV through injection drug use? 
a. Yes 
b. No 
c. Not sure 
3. Do you believe you can contract HIV from sexual contact? 
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a. Yes 
b. No 
c. Not sure 
4. Do you believe a baby can be born with HIV if the mother is HIV-positive? 
a. Yes 
b. No 
c. Not sure 
 
Section 4: This section aims to investigate your opinions on a possible HIV vaccine that could be 
available in the future. Please answer trustfully. 
 
1. If a HIV Vaccine were available, would you get immunized? 
a. Yes 
b. No 
c. Not sure 
2. If a HIV vaccine were available, would you get your child immunized? 
a. Yes 
b. No 
c. Not sure 
3. If a HIV vaccine were available, would you get immunized if it required one dose to be 
fully effective? 
a. Yes 
b. No 
c. Not sure 
4. If a HIV vaccine were available, would you get immunized if it required two doses to be 
effective? 
a. Yes 
b. No 
c. Not sure 
5. If a HIV vaccine were available, would you get immunized if it required three or more 
doses to be fully effective? 
a. Yes 
b. No 
c. Not sure 
6. If a HIV Vaccine was available, would you stop using condoms during sex if 
immunized? 
a. Yes 
b. No 
c. Not sure 
7. If an HIV Vaccine was available and you were immunized, would you engage in riskier 
sexual behavior? 
a. Yes 
b. No 
c. Not sure 
8. If an HIV vaccine was available and you were immunized, would you engage in behavior 
you did not engage in previously? 
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a. Yes 
b. No 
c. Not sure 
9. If men were to be immunized with an HIV vaccine, do you think that they would still get 
circumcised? 
a. Yes 
b. No 
c. Not sure 
10. Would you be concerned about how your sexual partner would react to you getting an HIV 
vaccine? 
a. Yes 
b. No 
c. Not sure 
11. Would you be concerned about how your family would react to you getting an HIV vaccine? 
a. Yes 
b. No 
c. Not sure 
12.  Would you get a HIV vaccine if it was not 100% effective against the virus? 
a. Yes 
b. No 
c. Not sure 
13. Do you think a HIV vaccine would lead to less people becoming infected with HIV? 
a. Yes 
b. No 
c. Not sure 
14. Are HIV vaccines more important for children or adults? 
a. Children 
b. Adults 
c. Not sure 
15. Are HIV vaccines more important for men or women? 
a. Men 
b. Women 
c. Not sure 
16. Do you think an HIV vaccination is better than PrEP? 
a. Yes 
b. No 
c. Not sure 
17. Would you support a compulsory HIV vaccine for all children? 
a. Yes 
b. No 
c. Not sure 
18. Would you support a compulsory vaccine for all HIV negative adults? 
a. Yes 
b. No 
c. Not sure 
19. Would you support a compulsory vaccination program for all HIV negative adults and 
children? 
a. Yes 
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b. No 
c. Not sure 
 
Appendix B 
Swahili Survey and Interview Questions 
 
Chanjo maswali ya uchunguzi 
 
Sehemu ya kwanza: Sehumu hii inalenga kuhusu maisha yako kwa ufupi na mambo kuhusu 
chanjo. Tafadhali jibu maswali haya (hizi) uwezavyo. 
 
1. Una miaka zaidi ya kumi na nane? 
a. Ndiyo 
b. Hapana 
2. Umesoma mpaka wapi? 
a. Sijaenda Shuleni 
b. Primary school 
c. Secondary school 
d. College 
e. Degree 
3. Wewe ni wa dini gani? Yani. 
a. Anglican 
b. Catholicism 
c. Islam 
d. Buddhism 
e. Baha’i 
f. Presbyterian 
g. Reformed 
h. Methodist 
i. Baptist 
j. Lutheran 
k. Pentecostal 
l. Eastern Orthodox 
m. New Apostolic Church 
n. Seventh-day Adventist Church 
o. Jehovah’s Witnesses 
p. United Pentecostal Church 
q. Branhamism 
r. The Church of Jesus Christ of Latter-days Saints 
s. Hinduism 
t. No religion 
u. Traditional Religion 
4. Una miaka mingapi? 
a. 18-20 
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b. 21-25 
c. 26-30 
d. 31-35 
e. 36-40 
f. 41-45 
g. 46-50 
h. 51-55 
i. 56-60 
j. 61-65 
k. 66-70 
l. 71-75 
m. 76-80 
n. 81-85 
o. 86-90 
p. 91-95 
q. 96-100 
r. 100+ 
5. Unakaa wapi/yani unaishi wapi? 
a. Kisumu County 
b. Siaya County 
6. Unamiliki nyumba/yani una nyumba yako? 
a. Ndiyo 
b. Hapana 
7. Wewe ni wa jinsia gani (yani wewe ni mwanamke au mwanaume)? 
a. Mwanaume 
b. Mwanamke 
8. Umewahi kupata chanjo mbeleni? 
a. Ndiyo 
b. Hapana 
9. Kama/ikiwa ndiyo, ulipata chanjo wakati ulikuwa mtoto au mtu mzima? 
a. Mtoto 
b. Mtu mzima 
c. Wakati ulikuwa mtoto na mtu mzima  
d. Sikupata chanjo yoyote 
10. Ulipata chanjo dhidi ya magonjwa gani? (Tafadhali jibu maswali haya (hizi) uwezavyo.) 
a. Adenovirus 
b. Anthrax 
c. Diphtheria 
d. Hepatitis A 
e. Hepatitis B 
f. Haemophilus influenza type b (Hib) 
g. Human Papillomavirus 
h. Seasonal Influenza (Flu) 
i. Japanese Encephalitis 
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j. Measles 
k. Meningococcal 
l. Mumps 
m. Pertussis 
n. Pneumococcal 
o. Polio 
p. Rabies 
q. Rotavirus 
r. Rubella 
s. Shingles 
t. Smallpox 
u. Tetanus 
v. Tuberculosis 
w. Typhoid Fever 
x. Varicella 
y. Yellow Fever 
 
 
Sehemu ya pili: Hii sehemu inalenga kujua maoni yako kuhusu chanjo. Tafadhali jibu maswali 
haya na sema ukweli. 
 
1. Unafikiri kwa ujumla chanjo ni nzuri au ni mbaya? 
a. Nzuri 
b. Mbaya 
c. Sijui 
2. Unafikiri chanjo zina madhara kwa afya? 
a. Ndiyo 
b. Hapana 
c. Sijui 
3. Unafikiri chanjo zinahitaji kuwa bure? 
a. Ndiyo 
b. Hapana 
c. Sijui 
4. Unaamini utaratibu wa afya? 
a. Ndiyo 
b. Hapana 
c. Sijui 
5. Unakubaliana na chanjo za lazima? 
a. Ndiyo 
b. Hapana 
c. Sijui 
 
Sehemu ya tatu: Hii sehemu inalenga kujua maoni yako kuhusu HIV/AIDS (ukimwi). Tafadhali 
jibu maswali haya na sema ukweli. 
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1. Uko sawa au huko sawa na watu ambao wana HIV? 
a. Niko sawa 
b. Siko sawa 
c. Hakuna msimamo 
d. Sijui 
2. Unaweza kupata HIV kupitia kwa sindano ya madawa ya kulevya? 
a. Ndiyo 
b. Hapana 
c. Sijui 
3. Unaweza kupata HIV kupitia kwa kufanya mapenzi (ngono)? 
a. Ndiyo 
b. Hapana 
c. Sijui 
4. Unaamimi mtoto anaweza kuzaliwa na HIV ikiwa mama yake ana HIV? 
a. Ndiyo 
b. Hapana 
c. Sijui 
 
Sehemu ya nne: Hii sehemu inalenga kujua maoni yako kuhusu kama chanjo ya HIV/AIDS 
(ukimwi) itaweza kupatikana siku za usoni (siku za bada ye). Tafadhali jibu maswali haya na 
sema ukweli. 
 
1. Kama kuna chanjo ya HIV ungependa kuchanjwa? 
a. Ndiyo 
b. Hapana 
c. Sijui 
2. Kama kuna chanjo ya HIV ungependa mtoto wako kuchanjwa? 
a. Ndiyo 
b. Hapana 
c. Sijui 
3. Kama kuna chanjo ya HIV ungependa kuchanjwa mara moja ili ifanye kazi vizuri mwilini? 
a. Ndiyo 
b. Hapana 
c. Sijui 
4. Kama kuna chanjo ya HIV ungependa kuchanjwa mara mbili ili ifanye kazi vizuri mwilini? 
a. Ndiyo 
b. Hapana 
c. Sijui 
5. Kama kuna chanjo ya HIV ungependa kuchanjwa mara tatu au zaidi ili ifanye kazi vizuri 
mwilini? 
a. Ndiyo 
b. Hapana 
c. Sijui 
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6. Kama kuna chanjo ya HIV ungependa kuacha kutumia condom kama umechanjwa? 
a. Ndiyo  
b. Hapana 
c. Sijui 
7. Kama kuna chanjo ya HIV na umechanjwa ungependa kuhatarisha maisha yako ukifanya 
mapenzi (ngono)? 
a. Ndiyo 
b. Hapana 
c. Sijui 
8. Kama kuna chanjo ya HIV na umechanjwa ungependa kuhatarisha maisha yako ukifanya 
mapenzi (ngono) kuliko zamani? 
a. Ndiyo 
b. Hapana 
c. Sijui 
9. Kama wanaume wangechanjwa na chanjo ya HIV unafikiri bado wangetahiriwa? 
a. Ndiyo 
b. Hapana 
c. Sijui 
10. Ungejali vile mwenzio wa ngono (yani yule unafanya mapenzi naye) angekuchukulia 
kama angejua kwamba umepata chanjo ya HIV? 
a. Ndiyo 
b. Hapana 
c. Sijui 
11. Ungejali vile familia yako ingekuchukulia kama ingejua kwamba umepata chanjo ya HIV? 
a. Ndiyo 
b. Hapana 
c. Sijui 
12. Ungechanjwa kama ungejua kwamba chanjo ya HIV si asilimia mia moja kwa ubora? 
a. Ndiyo 
b. Hapana 
c. Sijui 
13. Unafikiri chanjo ya HIV itasaidia kupunguza idadi ya watu ambao wanaumbukizwa virusi 
(HIV)? 
a. Ndiyo 
b. Hapana 
c. Sijui 
14. Chanjo ya HIV ni muhimu kwa watoto au watu wazima? 
a. Watoto 
b. Watu wazima 
c. Sijui 
15. Chanjo ya HIV ni muhimu kwa wanawake au wanaume? 
a. Wanaume 
b. Wanawake 
c. Sijui 
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16. Unafikiri chanjo ya HIV ni bora kuliko PrEP? 
a. Ndiyo 
b. Hapana 
c. Sijui 
17. Ungekubaliana na mpango wa chanjo ya lazima kwa watoto wote? 
a. Ndiyo 
b. Hapana 
c. Sijui 
18. Ungekubaliana na mpango wa chanjo ya lazima kwa watu wazima wote ambao hawana 
virusi (HIV)? 
a. Ndiyo 
b. Hapana 
c. Sijui 
19. Ungekubaliana na mpango wa chanjo ya lazima kwa watu wazima wote ambao hawana 
virusi (HIV) na watoto wote? 
a. Ndiyo 
b. Hapana 
c. Sijui 
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Appendix C 
English Consent Form 
 
 
 
CONSENT FORM 
1. Purpose of this study 
The purpose of this study is to investigate the opinions surrounding the HIV vaccine in particular the 
acceptability of the HIV vaccine, possible behavior changes that could result from the vaccine coming 
to market, and the support of a compulsory HIV vaccine. The researcher will collect data by utilizing 
surveys and interviews on opinions surrounding the HIV vaccine. 
 
2. Rights Notice 
 
In an endeavor to uphold the ethical standards of all SIT ISP proposals, this study has been reviewed 
and approved by a Local Review Board or SIT Institutional Review Board. If at any time, you feel that 
you are at risk or exposed to unreasonable harm, you may terminate and stop the interview. Please take 
some time to carefully read the statements provided below. 
a. Privacy - all information you present in this interview may be recorded and safeguarded. If you 
do not want the information recorded, you need to let the interviewer know. 
 
b. Anonymity - all names in this study will be kept anonymous unless the participant chooses 
otherwise. Community of study participants may be used in the paper, and direct quotes can be 
used in the paper. If the study participant does not consent to this, then the study participant 
should inform the interviewer. 
 
c. Confidentiality - all names will remain completely confidential and fully protected by the 
interviewer. By signing below, you give the interviewer full responsibility to uphold this 
contract and its contents. The interviewer will also sign a copy of this contract and give it to 
the participant. 
 
_________________________                                 _____________________________ 
Participant’s name printed                                         Participant’s signature and date                                                        
_________________________                                 _____________________________ 
Interviewer’s name printed                                        Interviewer’s signature and date 
 
3. Acknowledgement and Disclosure of HIV Vaccine Information 
 
The HIV vaccine is not currently on the market, and the immunization is not available to the general 
public. The HIV vaccine is projected to be on the market for public immunization within the next five 
to ten years. By signing below, you acknowledge that you understand the the HIV Vaccine is 
currently not available to the the general public. 
 
_________________________                                 _____________________________ 
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Participant’s name printed                                         Participant’s signature and date                                                        
_________________________                                 _____________________________ 
Interviewer’s name printed                                        Interviewer’s signature and date 
Appendix D 
Swahili Consent Form 
 
Fomu ya idhini 
4. Lengo la huu uchunguzi 
Lengo la huu uchunguzi ni kuchunguza maoni kuhusu chanjo ya HIV pamoja na kukubali. Chanjo ya 
HIV, uwezekano wa mabadiliko ya tabia ambayo inaweza kuleta matokeo kutoka kwa chanjo 
ambayo itapatikana na uungaji mkono wa lazima wa hii chanjo. Mtafiti atakusanya maelezo (data) 
kwa kutumia maswali na mahojiano. 
 
5. Haki za Ilani 
 
Katika juhudi za kutekeleza viwango vya maadili ya mapendekezo yote ya uchunguzi wa SIT. 
Uchunguzi huu umekaguliwa na kupitishwa na kamati au taasisi ya uangalizi ya SIT. Kama kwa wakati 
wowote ule unahisi kwamba uko hatarini unaweza kukatiza haya mahojiano. Tafadhali chukua 
wakati wako kwa makini na usome maelezo hapo chini.  
 
d. Faragha – Maelezo yote utakayotoa katika mahojiano haya yanaweza kurekodiwa na 
kuhifadhiwa. Kama hutaki maelezo haya kurekodiwa unahitaji kumwelezea mwenye kukuhoji. 
 
e. Kutojulikana -  majina yote katika uchunguzi huu hayatajulikana isipokuwa kama mhusika 
(mhojiwa) anaamua yajulikane. Jamii ya wahusika wa uchunguzi inaweza kutumiwa katika 
uchunguzi na yale yatakayotolewa yataweza kutumiwa katika huu utafiti moja kwa moja. 
Kama mhusika hatoi idhini, kwa hivyo mhusika wa uchunguzi anahitaji kumwambia mwenye 
kumhoji. 
 
f. Usiri – Majina yote yatawekwa kwa siri kabisa na kulindwa kabisa na mwenye kukuhoji. Kwa 
kutia sahihi hapo chini unampa mwenye kukuhoji jukumu kamili la kutekeleza huu mkataba 
na yaliyomo. Mwenye kukuhoji atatia sahihi kwenye hii nakala (kopi) kumkabidhi mhusika 
(mhojiwa) nakala hii. 
_________________________                                 _____________________________ 
Jina la mhusika      Sahihi ya mhusika na terehe 
_________________________                                 _____________________________ 
Jina la mwenye kuhoji                                         Sahihi mwenye kuhoji na terehe 
 
6. Kukubali na kueleza maelezo ya chanjo ya HIV 
 
Chanjo ya HIV haitumiki na kuchanjwa hakupatikani kwa watu wote. Chanjo hii inakusudiwa 
kutumika baada ya miaka mitano au kumi ijayo. Kwa kutia sahihi hapo chini unakubali kwamba 
unafahamu chanjo ya HIV kwa sasa haipatikani kwa watu wote. 
_________________________                                 _____________________________ 
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Jina la mhusika      Sahihi ya mhusika na terehe 
_________________________                                 _____________________________ 
Jina la mwenye kuhoji                                         Sahihi mwenye kuhoji na terehe 
Appendix E 
Focus Group Questions 
English: 
1. In Kenya, how do you believe immunizations are viewed? 
2. Do you think HIV is a major problem in Kenya? 
3. What kind of people get HIV? 
4. Considering the fact HIV can be transmitted through sexual intercourse, would you be 
willing to have your children vaccinated for HIV? 
5. If the HIV vaccine is released to the general public, do you think the HIV vaccine should 
be compulsory? Why or why not? 
6. Who do you think most needs to be vaccinated? 
Kiswahili: 
1. Katika Kenya unafikiri watu wanachukuliaje chanjo? 
2. Unafikiri HIV (virusi) ni shida kubwa katika Kenya? 
3. Ni watu aina gani wanapata virusi (HIV)? 
4. Ikilinganishwa kwamba virusi (HIV) vinaweza kuambukizwa kupitia kufanya mapenzi 
(yani ngono) ungependa watoto wako wapate chanjo ya virusi (HIV)? 
5. Chanjo ya virusi (HIV) ikiletwa kwa raia unafikiri chanjo itahitaji kuwa ya lazima? Kwa 
nini ndiyo na kwa nini hapana? 
6. Unafikiri nani zaidi anahitaji kuchanjwa? 
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Appendix F 
ISP Daily Journal 
Independent Study Project Daily Journal 
 
Week #1: (13/11/2017-19/11/2017) 
Monday: Today, I met with the community health volunteer that Vincent Obiero from KEMRI 
connected me with to work on the study, Ayub Saidi. We discussed the location of the study, the 
way we would collect surveys, and the way we would recruit people for focus groups. We 
decided to use other CHVs to recruit people and organize the focus groups. The surveys will be 
conducted by going to homes of people in Kondele that are either low-income or middle-income. 
We are still brainstorming on how to collect surveys and organize the focus group for the high-
income group. 
 
Tuesday: We visited the assistant chief of Kondele to get his approval and consent to conduct the 
study in Kondele, and he gave us a stamped letter that showed his approval. We then conducted a 
few surveys to test the length of time it would take in the field and how people would respond to 
being asked to complete a survey. Overall, it went well, and we had a very positive response to 
asking people to complete the survey. As we left Kondele, we visited the chief of the area to 
greet him, and he gave his approval for the study as well. We traveled back into town, and later 
in the day the CHV came back into town to get survey materials for the next day. 
 
Wednesday: Today the CHV conducted surveys on his own in Kondele, and in the afternoon, he 
brought the surveys that were completed into town for me to receive. I input this data into a 
google form I have set up to track the data and generate a spreadsheet. I gave the CHV the 
surveys that were going to be conducted the next day. 
 
Thursday: The CHV conducted the surveys today, and he delivered them to me in the afternoon. 
I used this time to create an excel sheet with tables that will be used later for chi-squared test of 
independence when the data is tallied and an analysis is run. I input the data that the CHV gave 
me into my google form online. 
 
Friday: Today, we had a focus group with people from the Kondele area who are low-income. 
Thirteen people attended the focus group at the church, and they answered the six focus group 
questions that I wrote. I got really good responses from them, but it became clear that many 
members of the focus group lacked basic information about vaccines. I noted the responses in 
addition to the questions they asked me at the end of the focus group. After this, the CHV and I 
conducted surveys for the people in Kondele who are middle-income. It was challenging to find 
people, but we ended up having a total of 17 surveys for the day which was on target. The CHV 
conducted some surveys the night before and gave me those surveys today.  
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Saturday: Today, I met the CHV in Kondele, and we conducted more surveys for the people who 
live in Kondele that are middle income. We were able to get 16 surveys, and I commonly got a 
request to keep my pen from men that we surveyed, as well as questions about whether there was 
compensation for the survey. I traveled back to town after these surveys were finished. I took 
note of an interesting statement that one of the women completing the survey mentioned. She 
said in Swahili: the vaccine will increase promiscuousness so we should not have it. 
 
Sunday: Today I did not conduct any surveys or analysis. 
 
Week #2: (20/11/2017-26/11/2017) 
Monday: Due to the election result being announced today, I stayed in my homestay all day, but 
I did not have any Wi-Fi to conduct work or enter data. My CHV met me at my house in the 
morning, and I gave him the materials to conduct the focus group for the middle-income people 
that live in Kondele. He conducted the focus group, and he said he will give me the responses 
tomorrow when we meet in person if there is no tension in the Kondele area. 
 
Tuesday: Today, I met the CHV at the SIT office, and he gave me the responses of the 
participants of the focus group. After that, we decided to go talk to the churches about 
conducting the surveys for the high-income group. We went to the office of St. Stephen’s 
cathedral, and one of the church leaders gave us her consent to bring surveys to church on 
Sunday to collect views. She will announce about the survey after the service. However, she also 
suggested giving the survey to a member of the Millimani fellowship, such as my host mom, and 
distributing and collecting the survey at the fellowship. She also suggested traveling to Aga 
Khan Hospital to ask if we could interview or conduct focus groups there. At Aga Khan, we 
inquired at the front desk, and the man sent us to talk to the Executive Secretary who gave her 
consent. The head of nurses for the mother and baby clinic, where the surveys would be 
conducted while women waited for services, needed to give her consent. However, she was in a 
meeting, so the Executive Secretary said she would contact us when she checked with her. I am 
still waiting to hear back from her to see if we can survey and interview there. The CHV and I 
agreed that we would try to conduct as many surveys as possible at Aga Khan, and then get the 
rest of the surveys at church and the fellowship. We also agreed to do short interviews with about 
ten women in the clinic in place of a focus group because this would be a more feasible way to 
collect views. The same focus group questions will be used for these interviews. If we get 
approval, we will start these surveys on Thursday, but if we do not, then we will try to do the 
surveys at the fellowship while rethinking another way to conduct the focus group or the 
interviews. I spoke with the CHVs from Simenya tonight, and I am going to meet with them on 
Monday morning to go over the plan. 
 
Wednesday: I have contacted the woman from Aga Khan Hospital, and she said that the 
documents I left her with are being reviewed by the head of nursing. She said she would contact 
me with an update by the end of the day, but I never received any contact by the close of 
business. I used this time to input the data from my surveys and to reach out to my advisor about 
a meeting at the end of this week to review the data I have collected before moving out to Siaya 
county. Ayub and I agreed to visit Aga Khan in person tomorrow at 10AM to get an update on 
the approval of doing surveys there in the hopes that we can start surveying tomorrow if 
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possible. I am hoping to be able to complete all of the surveys and interviews at Aga Khan by 
Friday so that I do not have a delay in moving out to Siaya. 
 
Thursday: Today, the CHV and I visited Aga Khan Hospital to get an update in person, and they 
informed us that the study will need to be approved at a weekly meeting for us to be able to 
survey at their facility. This will take too long due to the fact that I am traveling out to Simenya 
on Sunday. We also visited the Catholic church in Millimani, and they gave us approval to 
survey. They will call people ahead of time to let them know that we will be surveying them on 
Sunday. 
 
Friday: The man from the church called me this morning asking for an unreasonable amount of 
money for transportation because he will need to travel back to Kisumu to help us. However, he 
only needs to call the people, and we will survey them on Sunday. I have decided to eliminate 
the high-income group because it is proving too difficult to find an institution to recruit people 
from for research. Door-to-door research is not feasible for this income bracket. I am hesitant to 
get views from only one church as well due to bias. The CHV and I have decided to survey the 
rest from low-income and middle-income parents in Kondele. Since I am not able to go to 
Kondele due to the election, the CHV will conduct the surveys, and then, he will deliver them to 
me when I return from Simenya most likely. I am hoping to meet with my advisor later today or 
tomorrow to discuss the data that has been found so far. 
 
Saturday: I retrieved the surveys from the Catholic church this morning since we are no longer 
going to survey the high-income income group. The CHV and I met to discuss the plan moving 
forward, and he will be surveying 28 more people from the low-income and middle-income 
groups within Kondele. This will bring us to 100 surveys, and I will receive these surveys when I 
return from Simenya. 
 
Sunday: Today, I traveled out to Simenya to start surveys in the rural area. 
 
Week #3: (27/11/2017-3/12/2017) 
Monday: Today, I met with the CHV I will be working with, Monica Atieno, at the Simenya 
Dispensary. The management staff at the dispensary informed us that I need to get county 
approval for the study to be able to move freely throughout Siaya county to survey. The CHV 
and I traveled to the Ministry of Health Office in Siaya. They told us that we can start to survey 
people, and we can pick up the county approval letter later in the week. We then traveled to 
Sidindi where Monica is based, and we surveyed about 20 people in the market area. After this, I 
traveled home and attempted to get in contact with the other CHV that I was connected with in 
the area, but she never showed up to the meeting we scheduled for the evening. 
 
Tuesday: Due to the inauguration today, the CHV and I agreed that it would be best to remain at 
home for the day and pick up surveying again tomorrow. 
 
Wednesday: Today, we surveyed people at their homes in the village of Sidindi, as well as in the 
market place in Sidindi because it was market day in the village. We walked around the market 
and gave surveys to people who were selling goods, and then the sellers returned the surveys to 
us when completed. We completed about 25 surveys today, and I have about 54 surveys 
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completed so far. There were some issues with the community health volunteer not 
understanding that the survey participants need to be parents with children, but all the surveys 
that I have witnessed being conducted have gone to people who look old enough to be parents 
and verbally told me they had children. However, I think I am going to administer extra surveys 
to compensate for the small amount that may have not had children who were surveyed. I also 
realized one of the surveys was completed by someone who was under 18 so this survey cannot 
be used. I set up a meeting with the CHV for Simenya that I was connected with, but she did not 
show up again for the meeting. I am going to proceed by just working with the CHV for Sidindi, 
and we have planned to finish the surveys tomorrow. The CHV is scheduling a focus group for 
Friday, as well as a trip to the Siaya County Ministry of Health to retrieve the Siaya County 
approval for the study. 
 
Thursday: I met the CHV this morning at her homestead, and she gave me the surveys that she 
picked up last evening. We walked to about five households that she is in charge of as a CHV, 
and people at each of these houses took the survey. We ran into a man on the way out of one of 
the households that was not happy about me being there and asked my intentions in doing 
research in this community. The man was clearly very drunk, and Monica and I kept moving 
from household to household. Monica had to go to a meeting in Simenya, so we stopped 
surveying around 11:30AM. However, I gave Monica the remaining surveys, and she is going to 
complete them this evening so that I can pick them up tomorrow when we conduct the focus 
group. 
 
Friday: This morning I talked to the person in charge of research for the Siaya County 
Department of Health, and she informed me that she needed my protocol in order to review the 
study to give it approval from the county. I met with Monica, where she gave me surveys she 
completed yesterday evening, and we traveled to Ugun’ja. I printed the protocol in Ugun’ja, 
which was just the draft proposal because she needs a hard copy for the records. Also, I attended 
an event for World AIDS Day in Ugun’ja, and then, the CHV and I traveled back to Sidindi 
where we conducted a focus group to gather their views in relation to the HIV vaccine. The focus 
group went well, and we were able to gather data, as well as answer questions the participants 
had about the vaccine. 
 
Saturday: Today I rested, and I edited the methodology section of the paper, as well as went 
through the paper and noted the parts of the paper I still need to write and edit. 
 
Sunday: I did not work on my ISP today. 
 
Week #4: (4/12/2017-10/12/2017) 
Monday: I went to the Siaya County Health Department this morning, and they informed me that 
the head of research was at Siaya County Club for a meeting. I traveled to Siaya County Club to 
give her my protocol, and I met with her briefly to discuss the study. She informed me that she 
would talk with Steve about the study, and she indicated that I would get the letter by email later 
in the week. I then traveled to Kisumu, where I extended my visa, and I communicated with the 
Community Health Volunteer I am working with in Kisumu to arrange a meeting for tomorrow 
to pick up the completed surveys from him. I emailed my professor from the United States to ask 
COMMUNITY PERCEPTION OF THE HIV VACCINE IN WESTERN KENYA  69 
for sample R code for a chi-squared test of independence in order to analyze the data in a more 
effective manner.  
 
Tuesday: Today I input all of the data from the surveys into the google form that I created online, 
and then, I exported this data into an excel spreadsheet for further analysis. 
 
Wednesday: I worked on the paper today, and I met with my advisor in the afternoon to discuss 
the project results and the paper. He gave me a lot of valuable feedback and helped to create a 
plan for writing the discussion section of the paper. I continued to work on the paper after this 
meeting. 
 
Thursday: I continued to work on the paper, and I start to proofread the paper. 
  
Friday: Today I edited my paper, and I created my presentation for Monday. 
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Appendix G 
ISP Review Sheet 
 
KENYA: URBANIZATION, HEALTH AND HUMAN RIGHTS 
 
ISP REVIEW SHEET 
 
This page should be completed and attached to your ISP paper as the final page. It is for the use of 
future SIT students interested in your topic and is intended to give them nuts and bolts information 
about the types of problems they can expect in the field, as well as the suitability of both the topic 
and the ISP site.  
 
1.  Your topic – suitability, development, accessibility 
 
My topic was Community Perception of the HIV Vaccine in Western Kenya, and the topic was 
actually easy to develop with the help of my advisor and the SIT staff. I originally was going to 
surveys and interviews, but the local community health volunteer suggested focus groups which 
worked really well. People were very accessible to survey, and I did not encounter any barriers to 
field work except for the issues with the election. 
 
2.  Location of field study – where you conducted your field study, who helped set it up (who was 
helpful and who was not, include names, addresses, and phone numbers), strengths and weaknesses 
of the site 
 
I did my fieldwork in Kondele in Kisumu County and in the village of Sidindi in Siaya County. I was 
connected with community health volunteers in each of these areas. Vincent Obiero 
(vobiero@kemricdc.org) from KEMRI set me up with the CHV in Kisumu, while Babu set me up 
with the CHV in Siaya. The CHV in Kisumu, Ayub Saidi, was extremely helpful and valuable. He 
would also travel into town to give me surveys that he conducted and to meet, which was very 
helpful. The CHV in Siaya, Monica, was very good, but she was consistently 2-3 hours late for any 
meeting we had. The Quality Assurance Officer in Siaya County for the study approval was 
extremely slow and not very helpful. Kondele was an extremely good place to collect surveys 
because there was a large amount of people in a small space, and the market in Sidindi was a good 
place to collect a lot of surveys at one time as well. My advisor, Victor Mudhune, was also very 
helpful, and he provided feedback on my paper at multiple stages, as well as helped me create a plan 
for my discussion section after collecting my results. 
3.  Nuts and bolts – where to get water & food, where to stay, bugs & other critters, other problems 
 
I stayed with my previous homestay families in both Kisumu and Siaya, and I did not encounter any 
issues with either of the homestays up to this point. They provided me with breakfast and dinner. In 
Kisumu, I would get lunch in the CBD, and in Siaya, I would go to my homestay for a snack or 
lunch. My homestay families had water at their homes, so I would fill up my bottles there. 
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4.  Other noteworthy comments 
 
I have no other noteworthy comments. 
 
